Cargando…
The Deubiquitinating Enzyme Inhibitor PR-619 Enhances the Cytotoxicity of Cisplatin via the Suppression of Anti-Apoptotic Bcl-2 Protein: In Vitro and In Vivo Study
After chemotherapy for the treatment of metastatic bladder urothelial carcinoma (UC), most patients inevitably encounter drug resistance and resultant treatment failure. Deubiquitinating enzymes (DUBs) remove ubiquitin from target proteins and play a critical role in maintaining protein homeostasis....
Autores principales: | Kuo, Kuan-Lin, Liu, Shing-Hwa, Lin, Wei-Chou, Chow, Po-Ming, Chang, Yu-Wei, Yang, Shao-Ping, Shi, Chung-Sheng, Hsu, Chen-Hsun, Liao, Shih-Ming, Chang, Hong-Chiang, Huang, Kuo-How |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830310/ https://www.ncbi.nlm.nih.gov/pubmed/31627336 http://dx.doi.org/10.3390/cells8101268 |
Ejemplares similares
-
PR-619, a General Inhibitor of Deubiquitylating Enzymes, Diminishes Cisplatin Resistance in Urothelial Carcinoma Cells through the Suppression of c-Myc: An In Vitro and In Vivo Study
por: Hsu, Fu-Shun, et al.
Publicado: (2021) -
Trifluoperazine, an Antipsychotic Drug, Effectively Reduces Drug Resistance in Cisplatin-Resistant Urothelial Carcinoma Cells via Suppressing Bcl-xL: An In Vitro and In Vivo Study
por: Kuo, Kuan-Lin, et al.
Publicado: (2019) -
The Deubiquitinating Enzyme Inhibitor PR-619 is a Potent DNA Topoisomerase II Poison
por: Cowell, Ian G., et al.
Publicado: (2019) -
The UCHL5 inhibitor b-AP15 overcomes cisplatin resistance via suppression of cancer stemness in urothelial carcinoma
por: Chow, Po-Ming, et al.
Publicado: (2022) -
MLN4924 Synergistically Enhances Cisplatin-induced Cytotoxicity via JNK and Bcl-xL Pathways in Human Urothelial Carcinoma
por: Ho, I-Lin, et al.
Publicado: (2015)